

Copy number variations in *SMN1* and *SMN2* are associated with the onset and severity of spinal muscular atrophy (SMA), but recent studies have demonstrated that carrier risk and disease severity may also be impacted by the presence of *SMN1* gene duplication variants and a disease modifier variant in *SMN2*, respectively. The AmplideX® SMA Plus Kit\* delivers comprehensive results for *SMN1* and *SMN2*, including accurate quantification of exon 7 copy number plus detection of relevant variants and gene hybrids, from a single reaction in less than four hours.

#### REDUCED COMPLEXITY

- Detection of relevant alterations in a single trace
- AmplideX Reporter Software automates calling and analysis
- Complete kit includes all reagents

#### **OPTIMIZED WORKFLOW**

- <4 hrs from DNA to data
- Flexible use on widely installed CE equipment
- Common workflow with AmplideX PCR/CE FMR1\* and CFTR\* assays eases implementation and training

#### **QUALITY RESULTS**


- High concordance with multiple reference methods
- Differentiates between 0, 1, 2, 3 and ≥4 copies for both SMN1 and SMN2
- Robust performance across extraction methods

### Amplidex SMA Plus Kit\* Workflow - <4 hrs from DNA to Data






# A COMPLETE PICTURE FROM A SINGLE TRACE



## RELIABLE PERFORMANCE<sup>†</sup>

# Excellent Concordance in Independent, Multisite Testing of >460 Samples





### **High Intralaboratory Precision**



### **Robust Performance Across Extraction Methods**



#### **ORDERING INFORMATION**

Part Number	Product Description	Number of Reactions
A00055	AmplideX® SMA Plus Kit*	50
A00056	AmplideX® SMA Plus Kit*	100

# For more information, please visit asuragen.com

\*CE-IVD for U.S. Export Only. †Milligan JN, et al. J Mol Diagn. 2021.

